Tehran University of Medical Sciences
home | Farsi
Print

Majid Davari

Contact Information
Tel: 02164121137
Fax: 02166482606
Academic Rank
Assistant Professor
School
Pharmacy
pharmacoeconomy and pharmaceutical management
About
CV last edited on: 2016/10/07

1.

Farsi


Speaking: Native, Reading: Native, Writing: Native
2.

English


Speaking: Good, Reading: Good, Writing: Good
3.

Arabic


Speaking: Poor, Reading: Good, Writing: Poor

Ph.D

1.

Economic Analysis of Public Health


1393-Present Tehran University of Medical Sci,Ph.D.
2.

Economics of Health Care


1393-Present Tehran University of Medical Sci,Ph.D.
3.

Pharmacoeconomics / Economic Evaluation


1387-Present Tehran University of Medical Sci,Ph.D.
4.

Modelling in Pharmacoeconomics


1387-1392 Shahid Beheshti Medical Universi,Ph.D.
5.

Economics of Health Policy


1387-1390 Isfahan University of Medical Sc,Ph.D.

Pharm D

1.

Pharmacy Management


1393-Present Tehran University of Medical S,Pharm D.
2.

Pharmacy Management


1386-1388 Isfahan University of Medical Sc,Pharm D.

M.Sc

1.

Pharmaceutical Policy


1389-1390 Azad University,M.Sc.

Supervisor

1.

Cost-effectiveness analysis of Topotecan in compared with Paclitaxel and Doxorubicin in treatment metastatic ovarian cancer


Behrooz Rajabkhah,
M.Sc, Health Technology Assessment, 2016
2.

Cost-Effectiveness analysis of pregabalin and gabapentin in management of neuropathic pain in spinal cord injury in Iran


Bahman Amani,
M.Sc, Health Technology Assessment, 2016
3.

Cost-Utility Analysis of Prophylaxis versus On-Demand treatment in patients with severe Hemophilia A in Iran


Zahra Gharib-Naseri,
Ph.D, Pharmacoeconomics & Pharmaceutical Management, 2016
4.

Cost -Effectiveness Analysis Of Cinacalcet For SHPTin ESRD patient on Haemodialysis in Iranian Pharmaceutical market


Niloufar Sharahi,
M.Sc, Pharmaceutical Monitoring , 2015
5.

The direct medical costs of acute lymphocytic leukemia (ALL) in children in Isfahan, Iran


Elham Khayyam,
M.Sc, Financial Management, 2013
6.

The impact of family physician programme on financial indicators in Charmahal & Bakhtyari province, Iran


Maryam Kheyri,
Ph.D, Social Medicine, 2013
7.

The direct medical costs of breast cancer in Iran


Farkhondeh Yazdan-Panah,
B.Sc, Pharmacy, 2012
8.

The direct medical costs of colorectal cancer in Iran


Said Massah,
Pharm D, Pharmacy, 2012
9.

The direct medical costs of Diabetes in Iran


Zahra Boroumand,
Pharm D, Pharmacy, 2012
10.

Cost–effectiveness analysis of cetuximab in treatment of colorectal cancer in Iranian pharmaceutical market


Mohammad Tabatabaei,
Pharm D, Pharmacy, 2011
11.

Evaluation of Equity in Pharmaceutical Services in Selected city of Kurdestan


Mohammad Saleh Amini,
Pharm D, Pharmacy, 2010
12.

Iranian Pharmaceutical Industry and the Challenges of Joining the WTO


Habib Rajaei,
Pharm D, Pharmacy, 2010
13.

Cost-Effectiveness Analysis of Trastuzumab in early stages of the breast cancer


Nastaran Heydarzadeh,
Pharm D, Pharmacy, 2010
14.

Cost-Effectiveness Analysis of Clopidogrel versus Ticlopidin in managing myocardial infarction after stent


Mostafa Hosseini,
Pharm D, Pharmacy, 2010
15.

Cost-Effectiveness Analysis of Colorectal Cancer Screening Methods in the Iran


Zahra Allame,
Pharm D, Pharmacy, 2009
16.

. Evaluation of Equity in Pharmaceutical Services in Selected city of Isfahan


Zahra Bakhshizade,
Pharm D, Pharmacy, 2009
17.

Effectiveness Analysis of Clopidogrel versus Ticlopidin in managing myocardial infarction after stent


Fatemeh Kodaei,
Pharm D, Pharmacy, 2009

Papers

English

1.

Health care resource utilization and cost of care for haemophilia A and B patients in Iran


Authors: Gharibnaseri, Z. Davari, M. Cheraghali, A. Eshghi, P. Ravanbod, R. Espandar, R. Hantooshzadeh, R.
Transfusion and Apheresis Science, Vol.54, No.1, Year. 2016,
2.

The Direct Medical Costs of Outpatient Cares of Type 2 Diabetes in Iran: A Retrospective Study


Authors: Majid Davari · Zahra Boroumand · Masoud Amini · Mohsen Hosseini
International journal of preventive medicine, Vol.7, No.1, Year. 2016,
3.

. Evaluation of equity in access to pharmaceutical services in selected cites of Isfahan province (Iran


Authors: Majid Davari, Elahe Khorasani, Zahra Bakhshizade, Marzie Jafarian Jazi, Mohsen Ghaffari Darab, Mohammad Reza Maracy
Journal of Pharmacoeconomics and Pharmaceutical Management, Vol.14, No.4, Year. 2015,
4.

Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market


Authors: Davari, M. Ashrafi, F. Maracy, M. Aslani, A. Tabatabaei, M.
Int J Prev Med, Vol.6, No.63, Year. 2015,
5.

Measuring Equity in Access to Pharmaceutical Services Using Concentration Curve; Model Development


Authors: Davari, M. Khorasani, E. Bakhshizade, Z. Jafarian Jazi, M. Ghaffari Darab, M. Maracy, M. R.
Iran J Pharm Res, Vol.14, No.4, Year. 2015,
6.

; Does Family Physician Programme in Iran Improve Financial Contribution of the patients


Authors: Khadivi, R. Kheyri M. Davari, M. Nourbakhsh SK
International Journal of Current Life Sciences , Vol.4, No.8, Year. 2014,
7.

Relationship between socioeconomic factors and request for caesarean delivery in nulliparous women in Niknafs educational health centre of Rafsanjan


Authors: Davari, M. Maracy, M.R. Mokhtari, M. Ghorashi Z
Health Information Management, Vol.10, No.2, Year. 2014,
8.

A Single Model For Determining Socioeconomic Status in Health Studies; A Crucial Step To Make The Results More Comparable


Authors: Davari, M. Khorasani, E. Bakhshizade, Z. Jafarian Jazi, M. Ghaffari Darab, M. Maracy, M. R.
Vol.17, No.7, Year. 2014,
9.

The Direct Medical Costs of Breast Cancer in Iran: Analyzing the Patient’s Level Data from a Cancer Specific Hospital in Isfahan


Authors: Davari, M. Yazdanpanah F, Aslani A, Hosseini M, Nazari AR, Mokarian F
International Journal of Preventive Medicine , Vol.4, No.7, Year. 2013,
10.

The direct medical costs of colorectal cancer in Iran; analyzing the patient's level data from a cancer specific hospital in Isfahan


Authors: .Davari, M. Emami, M.H. Maracy, M.R. et.al
. International Journal of Preventive Medicine, Vol.3, No.12, Year. 2012,
11.

The direct medical costs of colorectal cancer in Iran; analyzing the patient's level data from a cancer specific hospital in Isfahan


Authors: .Davari, M. Emami, M.H. Maracy, M.R. et.al
. International Journal of Preventive Medicine, Vol.3, No.12, Year. 2012,
12.

?Health care financing in Iran; is privatisation a good solution


Authors: Davari, M. Haycox, A. Walley, T
Iranian Journal of Public Health , Vol.41, No.7, Year. 2012,
13.

. The Iranian Health Insurance system; past experiences, present challenges and future strategies


Authors: .Davari, M. Haycox, A. Walley, T
Iranian Journal of Public Health , Vol.41, No.9, Year. 2012,
14.

Pharmacoeconomics; an appropriate tool for policy makers or just a new field of research in Iran


Authors: Davari, M
Iranian J of Pharmaceutical Research, Vol.11, No.1, Year. 2012,
15.

The estimation of direct medical costs of treating patients with chronic hepatitis B and C in Iran


Authors: Kalantari, H. Davari, M. Akbari, M. et al.
International Journal of Preventive Medicine, Vol.3, No.3, Year. 2011,
16.

Comparative study on costs and effects of noninvasive Helicobacter pylori diagnostic tests


Authors: Kazemi S, Daghaghzade H, Kazemi Y, Habibzade M, Moinzade F, Davari M, Tavakoli H, Imami, M.H,
Journal of Isfahan Medical School, Vol.29, Year. 2011,
17.

Pharmaceutical policy and market in Iran, past experiences and future challenges


Authors: Davari M. Walley T. Haycox A.
Journal of Pharmaceutical Health Services Research, Vol.2, Year. 2011,
18.

Cost-Effectiveness Analysis of Colorectal Cancer Screening Methods in the Iran


Authors: Allame, Z. Davari, M. Imami, M.
Archive of Iranian Medicine, Vol.14, No.2, Year. 2011,
19.

Sensitivity and specificity of colorectal cancer mass screening methods: a systematic review of the literature


Authors: Allameh, Zahra Davari, Majid Emami, Mohammad Hassan
Iranian Journal of Cancer Prevention, Vol.4, No.2, Year. 2011,
20.

HEALTH CARE CHALLENGES IN IRAN


Authors: Davari, M. Haycox, A., Walley, T.
Iranian Journal of Public Health, Vol. Suppl, Year. 2005,
21.

N.I.C.E. LESSONS FOR IRAN


Authors: Davari, Majid Haycox, Alan Walley, Tom
CELLULAR & MOLECULAR BIOLOGY LETTERS , Vol.9, No.Supplement, Year. 2004,

Farsi

1.

The direct medical costs of acute lymphocytic leukemia (ALL) in children in Isfahan, Iran


Authors: Davari M. Moafi A. Yarmohammadian M.H. Khayyam E.
Health Information Management, Vol.14, No.4, Year. 2015,
2.

A HTA system for Iran, luxury or a real need


Authors: .Davari, M. Walley, T., Haycox, A
Health Information Management, Vol.10, No.6, Year. 2014,
3.

Health Technology Assessment Programme for Iran; A Luxury or Real Need?


Authors: Davari, Majid Walley, Tom Haycox, Alan
Health Information Journal , Vol.10, No.6, Year. 2013,
4.

The economic challenges of health system in Iran


Authors: Davari, M
Health Information Management, Vol.8, No.7, Year. 2012,
5.

Promoting the efficient use of human resources in reproductive health services in Iran; a Cost-service analysis


Authors: Davari, M. Kohan, S. Enjezab, B. Javadnouri, M.
Health Information Management, Vol.8, No.7, Year. 2012,
1. Economic Evaluation

Economic evaluation is the process of systematic identification, measurement and valuation of the inputs and outcomes of two alternative activities, and the subsequent comparative analysis of these. The purpose of economic evaluation is to identify the best course of action, based on the evidence available. Economic evaluations can be completedby various forms such ascost effectiveness analysis and cost utility analysis.

2. Efficiency

Efficiency is a measurable concept that can be calculated by determining the ratio of useful output to total input. An efficiency study addresses the questions of Allocative efficiency or Technical efficiency. Allocative efficiency assesses competing programs and judges the extent to which they meet objectives. Technical efficiency assesses the best way of achieving a given objective.

3. Equity

Equity is defined as fairness or justice in the way people are treated. Within the context of health and health care, equity is divided in equity in access and equity in finance. Equity in access addresses systematic inequality of access to health care / health in different groups of people. Equity in health care financing is assessed by the degree of inequality in paying for health care between households of unequal Ability To Pay (ATP). It is usually represented by the extent to which health care is financed according to ATP. 

Top